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This study aims to determine the most frequent titers of anti-A 
and anti-B (both presumed immunoglobulin [Ig]M and IgG) in 
Iranian group O blood donors and to compare these titer values 
with those found in other studies. In addition, alloantibody 
production and plasma levels of four IgG subclasses were 
compared between the high-titer and non–high-titer study 
groups. This study investigated anti-A and anti-B titers in 358 
plasma samples. Based on these results, two study groups (high-
titer and non–high-titer) were formed. Antibody detection tests 
were performed to detect unexpected antibodies to D, C, c, E, 
e, K, k, Fya, Fyb, Jka, Jkb, M, N, S, s, P1, Lea, and Leb. Four IgG 
subclasses were also evaluated through nephelometry assay. 
The most frequent titer obtained by room temperature and 
indirect antiglobulin tube tests was 256. The frequency of titers 
≥512 was 31.5 percent. None of the cases showed unexpected 
RBC alloantibodies. IgG2 levels were significantly higher in the 
high-titer group. Evaluation of isoagglutinin titers in group O 
Iranian blood donors can provide insight into the frequency of 
isoagglutinin titers both within the Iranian population and as 
compared with other populations. A significant difference in 
IgG2 levels between the high-titer and non–high-titer groups was 
identified. More investigation needs to be conducted on the root 
cause of this finding. Immunohematology 2021;37:5–12.
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The presence of high levels of anti-A and anti-B in a blood 
plasma component can cause unfavorable immune responses 
in recipients. These immune responses may cause severe red 
blood cell (RBC) destruction that can also be fatal.1,2 There 
is an increased risk of hemolytic reactions after an ABO-
minor mismatched platelet transfusion.3,4 The U.S. Food and 
Drug Administration has also issued reports of death after 
the transfusion of plasma components with high levels of 
isohemagglutinins.5 Despite the fact that some transfusion 
service providers have a policy against using high-titer plasma 
components, specifically platelet concentrates, there is still a 
lack of agreement on the threshold titer value that would lead 
to an unsafe blood component.6,7 Diet, as well as ethnic and 
environmental factors, play a contributing role in the level 
of isoagglutinin titers in different populations; therefore, it is 
important to determine the frequency of high isoagglutinin 
titers in each population and also to determine the cutoff titer 
value that determines a plasma component to be unsafe.8,9
Unexpected alloantibodies are normally produced 
through immunization by blood transfusion or pregnancy. 
Alloantibodies such as anti-M, anti-P1, anti-H, and anti-I 
can occur without previous RBC exposure. It has been 
shown that microbial elements or environmental factors are 
also involved in alloantibody production.10 Alloantibodies 
are important in transfusion medicine and can cause 
complications, especially if they are present at high levels.11 
Alloantibodies to RBC antigens have been reported in about 
0.8 percent of blood donors.12
Generally, antibody formation against RBC antigens 
depends on many factors, including the nature of the antigen 
and its immunogenicity, environmental factors, and immune 
system variations in the individual. Antibodies can be produced 
at high levels in high responders.13,14 Immunoglobulin (Ig)G 
antibodies are typically clinically significant in transfusion 
medicine, and all four IgG subclasses can be produced in an 
individual with high-titer isoagglutinins.15
In this study, we aimed to find the most frequent titer 
of anti-A and anti-B (IgM and IgG) in Iranian group O 
blood donors. Because there are no previous studies on the 
frequency of isoagglutinin titers in Iran, our study will assess 
information from group O blood donors in this country for the 
first time to highlight the importance of studying isoagglutinin 
titers in each unique population. Furthermore, this study 
compares alloantibody production and plasma levels of four 
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Transfusion Organization (IBTO). Each sample was collected 
in a tube containing EDTA as an anticoagulant. About 10 mL 
of each blood sample was centrifuged at 200g for 5 minutes at 
22°C. Then, 4 mL RBC-free plasma was separated, aliquoted, 
and stored at –30°C until testing. A total of 358 plasma 
samples from both men and women donors with an age 
range of 18–68 years were tested. The samples were collected 
randomly within 11 months between November 2014 and 
October 2015.
Preparation of A1 and B RBC Suspensions
To prepare A1 and B RBCs for use in testing, 2 group A1, 
D– packed RBC units and 2 group B, D– packed RBC units 
were separately pooled. Testing of the pools confirmed their 
ABO group, a negative antibody detection test, and a negative 
direct antiglobulin test. The pooled RBCs were washed three 
or four times until a clear supernatant was reached. A 2–5 
percent RBC suspension was prepared with Alsever’s solution 
containing antibiotics. The method for preparing these RBCs 
was validated with commercial reagent group A1 and B RBCs 
from Bio-Rad (Cressier FR, Switzerland).
Tube Test
Twofold serial dilutions in normal saline (0.9%) from 1:2 
to 1:1024 were made for each sample. If necessary, higher 
dilutions were prepared. For each sample, 100 µL diluted 
plasma was transferred to the next tube in sequence until 
the final dilution was reached. Two sets of diluted tubes were 
prepared for each sample: one to determine IgM titer and one 
to determine IgG titer of anti-A and anti-B.
The room temperature (RT) method was used as a 
semiquantitative method to determine IgM titer.16–18 By this 
method, 100 µL of each dilution was incubated with 50 µL of 
the 2–5 percent pooled A1 or B RBCs separately in a tube test 
for 1 hour at RT. After incubation, samples were centrifuged 
immediately at 1060g for 15 seconds (EBA 21 centrifuge; 
Hettich, Kirchlengern, Germany). Results were read starting 
from the tube with the lowest plasma concentration (1:1024). 
The titer endpoint was the highest dilution with visible 
agglutination (1+ reactivity) after gentle shaking. 
To determine IgG titer, an indirect antiglobulin test (IAT) 
was performed. By this method, 100 µL diluted sera was 
incubated with 50 µL of the 2–5 percent pooled A1 or B RBCs at 
37°C for 45 minutes and then washed three times to eliminate 
unattached antibodies. Two drops of polyspecific antihuman 
globulin (AHG) (anti-IgG/anti-C3d; Bio-Rad, Feldkirchen, 
Germany) were added to each tube.18,19 IgG-coated reagent 
RBCs (in-house preparation; IBTO, Tehran, Iran) were added 
to each tube with a negative reaction to validate the washing 
process. Endpoint titers were determined in the same way as 
that for the RT method.
Column Agglutination Technology 
Because both IgM and IgG antibodies may participate 
in agglutinating RBCs using RT and IAT methods, samples 
with initial titers >256 (113 of 358 samples) were evaluated 
by semi-automated column agglutination technology (CAT).20
TreaTmenT of Plasma wiTh DTT
Dithiothreitol (DTT) (0.01 M) was used to inactivate 
IgM antibody in the plasma samples before testing by CAT. 
The DTT was prepared by dissolving 0.154 g DTT powder 
(BDH Chemicals, Poole, UK) in 100 mL phosphate-buffered 
saline (pH 7.3). The positive control was prepared using 
monoclonal anti-D (IgM, D-13088 [Sifin, Berlin, Germany] 
monoclonal test reagent) diluted 1:4 in 2 percent albumin. The 
negative control was an IgG anti-D (CE-Immunodiagnostica, 
Eschelbronn, Germany). To inactivate the IgM antibodies, 1 
mL of each donor plasma sample was incubated with 1 mL of 
0.01 M DTT at 37°C for 1 hour. For the positive and negative 
controls, 100 µL of each control was treated with 100 µL of the 
0.01 M DTT.
TesTing by CaT
Twofold serial dilutions of each DTT-treated plasma from 
1:2 to 1:1024 were made. Finally, 25 µL of diluted plasma and 
50 µL of the A1 or B RBC suspensions diluted to 0.8 percent 
(INVITROLISS; MTC Invitro Diagnostics AG, Bensheim, 
Germany) were added to the low-ionic-strength solution 
(LISS)/Coombs card (AHG-Coombs MTC; MTC Invitro 
Diagnostics AG). IAT results were recorded after the cards 
incubated at 37°C for 15 minutes and then centrifuged at 85g 
for 10 minutes. The endpoint titer was the highest dilution 
giving visible macroscopic agglutination (1+ reactivity).
Since some of the blood donor samples showed high 
levels of isoagglutinins, even without previous RBC exposure, 
it became of interest to investigate alloantibody production 
and IgG subclasses. In this study, we compared levels of 
alloantibody and IgG subclasses within two groups of 
individuals (high-titers vs. non–high-titers). Thus, 22 plasma 
samples (11 samples with titers greater than 512 [high-titer 
group] and 11 samples with titers less than 128 [non–high-
titer group]) were selected randomly. Unexpected antibodies 
and IgG subclasses were evaluated on these samples. 
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Alloantibody Detection
The presence of antibody against D, C, c, E, e, K, k, 
Fya, Fyb, Jka, Jkb, M, N, S, s, P1, Lea, and Leb antigens was 
evaluated using standard reagent RBCs: Cell I, Cell II, and Cell 
III. These three reagent RBCs were prepared according to the 
Immunohematology Reference Laboratory at IBTO.
Three tubes were labeled as I, II, and III for each sample, 
and two drops of plasma were added to each tube. One drop 
of reagent RBCs I, II, and III was added to the labeled tubes, 
respectively. Tubes were centrifuged at 1000g for 15–20 
seconds, and hemagglutination or hemolysis was examined 
in each tube. Two drops of LISS were added to each tube as 
an enhancer. After a 10- to 15-minute incubation at 37°C, the 
tubes were centrifuged and examined. The results were read 
and recorded. Then, after washing three times, polyspecific 
AHG was added to the tubes. After centrifugation, each tube 
was read for agglutination and the final result immediately 
recorded. To validate the negative AHG results, one drop of 
sensitized RBCs (IgG-coated control RBCs) was added to 
tubes with negative results.21 (Note: IgG-coated control RBCs 
were prepared in-house by incubating anti-D reagent [Anti-D 
incomplete, titer = 128; CE-IMMUNODIAGNOSTIKA, Gmbh, 
Neckargemund, Germany] diluted to adjust titer, as needed, 
with 6% albumin [Iranian Blood Research and Fractionation 
Co., Tehran, Iran]) with D+ RBCs at 37°C for 60 minutes and 
then washed three times to remove the supernatant.) This 
control showed ≤2+ results by the IAT, thus validating the 
negative AHG reactions.
IgG Subclasses
Plasma levels of IgG1, IgG2, IgG3, and IgG4 (mg/L) 
were measured by nephelometry assay using the Binding 
Site kit (MININEPH, Birmingham, UK). A total of 40 µL 
MININEPH Hu reagent plus 400 µL specific buffer were 
added to the defined amounts of plasma dilution according 
to the manufacturer’s instructions (for IgG1, 10 µL of 1:11 
plasma dilution; for the other three subclasses, 20 µL of 1:121 
dilution). High- and low-level controls were used in the assays 
according to the manufacturer’s instructions.
Statistical Analysis
All data were analyzed by standard statistical software 
(SPSS, Chicago, IL). A p value <0.05 was considered 
statistically significant. To evaluate the distribution of the 
high-titer isoagglutinins in different age ranges and also by 
different methods of titration, Kruskal-Wallis and Mann-
Whitney tests were used. A comparison between the two 
groups (high-titer and non–high-titer) was performed in 




Among 358 samples, the frequencies of titration endpoints 
≥512 in the four measured titers were as follows: IgM anti-A 
(10.3%), IgM anti-B (5.5%), IgG anti-A (23.4%), and IgG 
anti-B (12.3%). The frequencies of anti-A titers (IgM and 
IgG) ≥512 was higher than those of anti-B titers (IgM and 
IgG) (p = 0.0001). The detailed results are shown in Table 1. 
Figure 1 depicts the frequency of titer endpoints for IgG (anti-A 
and anti-B) and IgM (anti-A and anti-B). 
Table 1. Frequency of the highest titer of anti-A and anti-B 
observed with IgM and IgG antibodies in tube testing
IgM IgG
Endpoint titer Anti-A, n (%) Anti-B, n (%) Anti-A, n (%) Anti-B, n (%)
512 27 (7.5) 17 (4.7) 64 (17.9) 37 (10.3)
1024 9 (2.5) 3 (0.8) 17 (4.7) 7 (2.0)
2048 0 0 3 (0.8) 0
4069 1 (0.3) 0 0 0
≥512 37 (10.3) 20 (5.5) 84 (23.4) 44 (12.3)
Fig. 1 The frequency (%) of titer endpoints (16–4096) for IgG 
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Among 358 group O blood donors, 113 samples showed at 
least one endpoint titer ≥512 when tested by tube method (RT 
or IAT), giving a titer frequency of 31.5 percent. (Note: when 
both IgM and IgG titers were ≥512, they were counted as one 
case.) A total of 30 samples (8.3%) showed a titer >512. Only 
three samples (0.8%) had a titer >1024.
Figure 2 shows a comparison between men and women 
group O blood donors in our study population. Most of the 
randomly selected donors were men (329, 91.9%); only 29 
(8.1%) female donors were included in our study. Although 
men constituted the majority of donors in this study, the 
percentage of titers ≥512 was higher among women (48.2% 
vs. 21.1%). Table 2 compares high-titer values within the 
male and female populations. Among men, 30 (9.1%) and 
70 (21.1%) samples showed a titer ≥512 for IgM anti-A and 
IgG anti-A by tube method, respectively. For anti-B titers, 17 
(5.1%) and 39 (11.8%) of the samples from men had a titer 
≥512 for IgM and IgG, respectively. In women, 8 (27.5%) and 
14 (48.2%) samples were observed with a titer ≥512 for anti-A 
IgM and IgG, respectively. Anti-B titers of ≥512 in samples 
from the women were found at 10.3 percent (n = 3) and 17.2 
percent (n = 5) for IgM and IgG, respectively. Considering a p 
value <0.05 as significant, the comparison shows that high-
titer IgM anti-A and IgG anti-A are more prevalent in women 
(p = 0.002 and 0.001, respectively).
Donors having anti-A or anti-B titers ≥512 (RT or IAT) 
were divided into five age ranges (Figs. 3 and 4). This analysis 
showed no significant relationship between age range and the 
probability of titers ≥512 except for IgM anti-B (RT method). 
The frequency of titers ≥512 for IgM anti-B is lower in the 
39–48 years age range in comparison with other age ranges 
(p = 0.019).
CAT-DTT Results
We tested 113 samples having titers ≥512 by CAT after 
DTT treatment of the plasma (CAT-DTT). The titer after DTT 
treatment decreased to ≤256 in 85 samples for anti-A and in 
91 samples for anti-B. The mean titer decreased by one or two 
dilutions in CAT-DTT tests. Twenty-eight of 113 (7%) samples 
had IgG titers for anti-A, and 22 samples (19.4%) had IgG titers 
for anti-B ≥512 in CAT-DTT tests (18 samples: 512; 9 samples: 
1024; and 1 sample: 2048). Because IgG is best active at 37°C, 
it is better that it be measured without the influence of IgM.21 
Table 3 shows endpoint titers of donors classified by test 
method (RT, IAT, and CAT-DTT methods).
Alloantibody Detection Results
Results showed no unexpected alloantibody(ies) detected 
in any of the samples. Considering the fact that high-
titer isoagglutinins are present in some blood donors, our 
investigation showed that there was no relation between the 
incidence of potentially unsafe group O donors with titers 
≥512 and alloantibody production.
Results of IgG Subclasses
Evaluating the levels of four IgG subclasses in high-titer 
and non–high-titer groups showed a significant difference in 
IgG2 levels between the two groups. Other IgG subclasses 
did not display any significant differences. Comparisons are 
shown in Figure 5 (p < 0.05 was considered significant).
Discussion
Frequency of Anti-A and Anti-B Titers Vary in 
Different Populations
According to an international forum, high-titer iso-
agglutinins are a potential problem in transfusion medicine, 
and a critical titer should be determined as a cutoff for 
plasma components when considering transfusion of these 
Table 2. Percentage of titers ≥512 for male and female donors
Room temperature Indirect antiglobulin test
Donors Anti-A, % (n) Anti-B, % (n) Anti-A, % (n) Anti-B, % (n)
Men 9.1 (30) 5.1 (17) 21.1 (70) 11.8 (39)
Women 27.5 (8) 10.3 (3) 48.2 (14) 17.2 (5)
Men vs. women
p 0.002 0.25 0.001 0.4
Odds ratio 3.8 2.1 3.5 1.55
95% CI 1.55–9.3 0.58–7.7 1.59–7.49 0.56–4.3
CI = confidence interval.
Fig. 2 Comparison of titers by male and female group O blood 
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components to patients with ABO-incompatible RBCs.18 
Because the titer of isoagglutinins is affected by environmental 
factors as well as immune system variations in the donor, the 
frequency of high-titer isoagglutinins could vary in various 
populations. Therefore, it is essential to determine the 
prevalence of high-titer cases in each population.8,22 Testing 
of anti-A/-B titers in several countries showed variation in 
testing methods as well as differences in the critical high-titer 
cutoff value (Table 4).2,18,22–26
Isoagglutinins in Iranian group O donors
Table 3. Endpoint titers of donors classified by test method (N = 113)
Room temperature Indirect antiglobulin test CAT-DTT
Endpoint titer Anti-A, % (n) Anti-B, % (n) Anti-A, % (n) Anti-B, % (n) Anti-A, % (n) Anti-B, % (n)
16 0 0.8 (1) 0 0 0 0
32 0 3.5 (4) 0 1.7 (2) 0 0
64 5.3 (6) 15 (17) 0 4.4 (5) 5.3 (6) 6.1 (7)
128 18.5 (21) 31.8 (36) 5.3 (6) 22.1 (25) 18.5 (21) 28.3 (32)
256 43.3 (49) 30.9 (35) 20.3 (23) 32.7 (37) 51.3 (58) 46 (52)
512 23.8 (27) 15 (17) 56.6 (64) 31.8 (36) 15.9 (18) 12.3 (14)
1024 7.9 (9) 2.6 (3) 15 (17) 6.1 (7) 7.9 (9) 7 (8)
2048 0 0 2.6 (3) 0 0.8 (1) 0
4096 0.8 (1) 0 0 0 0 0
CAT-DTT = column agglutination technology using dithiothreitol-treated plasma.
Fig. 3 Frequency (%) of titers ≥512 in different age ranges observed 
in room temperature (RT) testing by tube method. *IgM anti-B titer 
is lower in the 39–48 years age range in comparison to other age 





























Fig. 5 Comparison of immunoglobulin (Ig)G subclass levels in 
plasma samples from high-titer and non–high-titer groups. The p 
value is shown in each evaluation, and p < 0.05 was considered 
significant. The amount of IgG2 subclass showed a significant 

























































p value = 0.9738
Fig. 4 Frequency (%) of titers ≥512 in different age ranges observed 
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Several studies have been performed to understand 
the severity of complications caused by the high level of 
isoagglutinins through transfusion.6,27 There is no universal 
agreement on a critical titer and methodology. Nevertheless, 
the RT tube method is generally performed, and titer endpoint 
of 128 has been determined as a critical titer in many 
countries.28 In the gel method and other automated systems, 
titer endpoints differ from those for the tube method.29 This 
finding also applied to our study.
In this study, 128 (IgM) and 256 (IgG) are the most 
frequently observed titers; these titers are considerably 
higher than critical titers in many countries. Only a few 
samples were found with a titer <64 or >512. We have shown 
that the prevalence of titers ≥512 is higher among women. 
Based on other studies, higher ABO antibody formation in 
women could be due to more sensitization from pregnancy 
or infections.30–32 The isoagglutinin titer is important in 
transplantation (especially bone marrow transplantation) and 
early spontaneous abortion as well.33–36
Isoagglutinins that sensitize or agglutinate at 37°C, 
especially at higher titers, may be the most potentially critical. 
On the other hand, ABO antibodies reactive at RT probably 
do not cause any clinical complications. In this study, the 
frequency of titers >512 was 8.4 percent and the frequency 
of titers ≥512 was 31.5 percent using the tube method. These 
findings are comparable with high-titer cases in Brazilian 
(30%) and Italian (27%) studies.37,38 Our study was an in vitro 
investigation that, for the first time, showed the most frequently 
encountered titers of ABO antibodies in Iranian donors and 
compared titer values in male and female donors as well as 
within age ranges of these donors. We note that a clinical study 
is also required to determine potentially clinically critical titers 
in practice.
Alloantibodies and IgG Subclasses
This study, for the first time, evaluates alloantibodies 
and IgG subclasses in high-titer and non–high-titer group O 
blood donors in the Iranian population. It has been shown 
that different antibody responses against polysaccharides 
and susceptibility to different bacterial infections are probably 
under the control of genetic conditions and have a relationship 
with total IgG2 levels in serum.39,40 In high responders, IgG2, 
IgG3, and IgG4 are produced at higher levels in comparison 
with low responders, who have different allotype heavy 
chains.41 Immunoglobulin allotypes are related to high and 
low antibody responses, and a high responder against a 
particular antigen may also be a high responder to many other 
antigens. This statement is also true about low responders.39 
In our study, the plasma level of IgG2 was significantly 
higher in the high-titer group. We did not find any correlation 
between high isoagglutinin production and unexpected 
RBC alloantibody production. It is of note that while most 
of the non-ABO RBC antigens to which clinically significant 
alloantibodies are formed are proteins or glycoproteins, 
ABO antigens are carbohydrates. Naturally occurring anti-T, 
directed at a carbohydrate antigen, may be a better antibody 
for comparison. 
In conclusion, our study shows that the most frequent titer 
of ABO antibodies in Iran is 256, and the frequency of titers 
≥512 is 31.5 percent in group O blood donors using the tube 
method. Additionally, no connection between alloantibody 
and isoagglutinin production was observed in this study. IgG2 
levels were found significantly higher in donors with high 
levels of isoagglutinins.
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